Trial · NCT03214081
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Who Had One or More Adverse Drug Reactions | Up to 12 months | Safety Analysis Set, The safety analysis set was defined as all participants who completed the survey. | Percentage of Participants | NUMBER |
| SECONDARY | Endoscopic Relapse Rate | From the initiation of the maintenance therapy to Month 12 (or discontinuation of the therapy), up to 12 months | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. | Percentage of Participants | NUMBER |
| SECONDARY | Number of Participants With Recorded Severity of Subjective Symptoms of Heartburn | Baseline, Month 6 and at Month 12 | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. Number analyzed is the number of participants who were evaluable at each time point. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Recorded Severity of Subjective Symptoms of Acid Reflux | Baseline, Month 6 and at Month 12 | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. Number analyzed is the number of participants who were evaluable at each time point. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Recorded Severity of Subjective Symptoms of Postprandial Fullness | Baseline, Month 6 and at Month 12 | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. Number analyzed is the number of participants who were evaluable at each time point. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Recorded Severity of Subjective Symptoms of Early Satiation | Baseline, Month 6 and at Month 12 | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. Number analyzed is the number of participants who were evaluable at each time point. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Recorded Severity of Subjective Symptoms of Epigastric Pain | Baseline, Month 6 and at Month 12 | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. Number analyzed is the number of participants who were evaluable at each time point. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Recorded Severity of Subjective Symptoms of Epigastric Burning | Baseline, Month 6 and at Month 12 | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. Number analyzed is the number of participants who were evaluable at each time point. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Recorded Severity of Subjective Symptoms of Abdominal Bloating | Baseline, Month 6 and at Month 12 | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. Number analyzed is the number of participants who were evaluable at each time point. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Recorded Severity of Subjective Symptoms of Nausea/Vomiting | Baseline, Month 6 and at Month 12 | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. Number analyzed is the number of participants who were evaluable at each time point. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Recorded Severity of Subjective Symptoms of Belching | Baseline, Month 6 and at Month 12 | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. Number analyzed is the number of participants who were evaluable at each time point. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With Recorded Severity of Subjective Symptoms of Anorexia | Baseline, Month 6 and at Month 12 | Efficacy assessment population, The efficacy assessment population was defined as participants who completed the survey and had efficacy data at baseline and post-baseline time points available. Number analyzed is the number of participants who were evaluable at each time point. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03214081/outcomes